Business
Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering
Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering.
About this update from Cardax Inc
[{"type":"text","content":"\n\n\n\nCardax Files Registration Statement for Proposed $15 Million Follow-On Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prnsbtb0{\nBORDER-BOTTOM:black 0pt\n}\n\n\n\n\n\n\nCardax Files Registration Statement for Proposed $15 Million Follow-On Offering\n- Maxim Group to serve as sole book running manager on a firm commitment basis\n- Funds to be used primarily for pharmaceutical development\n- Concurrent Nasdaq uplisting planned\nPR Newswire\nHONOLULU, Aug. 14, 2019\n\n\n\nHONOLULU, Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of up to $15 million of the Company's common stock and warrants. The number of securities to be offered and the price range for the offering have not yet been determined. Cardax is in the process of applying to list its common stock on the Nasdaq Capital Market. Maxim Group LLC (\"Maxim\"), a leading full-service investment bank, is acting as the sole book running manager on a \"firm commitment\" basis for the proposed offering.\nCardax expects that the net proceeds of the proposed follow-on public offering will provide the Company with sufficient resources to develop its CDX-101 pharmaceutical candidate through IND and Phase I clinical testing and to complete its CHASE clinical trial targeting cardiovascular inflammatory health with its ZanthoSyn® astaxanthin dietary supplement.\nA registration statement relating to these securities has been filed with the Secu...